恶性血液病炎症因子CD_(62p)、CD_(11b)、PMA表达特征

Expression of P-selectin, CD_(11b) and Platelet Monocyte Aggregate in Malignant Hematopoietic Diseases

目的探讨炎症因子CD62p(P-选择素)、CD11b、血小板-单核细胞聚合体(PMA)在恶性血液病不同病期的表达特征及临床意义。方法用流式细胞仪检测77例恶性血液病患者及30例正常人CD62p、CD11b及PMA的表达情况。结果恶性血液病初治时CD62p、CD11b、PMA表达水平高于对照(P<0.05);急性白血病(AL)缓解时各因子的表达水平低于初治(P<0.05),部分缓解(PR)时炎症因子的表达水平高于对照(P<0.05),CR期与对照组比较差异无显著性(P>0.05)。结论恶性血液病发病时存在易栓状态;急性白血病各病期CD62p、CD11b、PMA的表达不同,可作为临床疗效观察、预后判断的指标之一。

Objective To investigate the expression of P-selectin （CD62p）, CD11b and platelet-monocyte aggregates （PMA） in malignant hematopoietic diseases and their clinical significance Methods The CD62p, CD11b and PMA expressions in blood samples from 77 malignant hematopoietic diseases and 30 healthy people were measured by flow-cytometric analysis. Results （1） The expressions of CD62p, CD11b and PMA stepped up in initial treatment patients compared with control patients, （2） The remission patients after therapy in acute leukemia expressed lower levels of these factors than initial treatment group whereas PR group expressed higher levels than control group（P 〈 0.05）, There was no difference between CR group and control group （P 〉0.05）. Conelusion Our observations suggest that high levels of CD62p, CDllb and PMA in acute state of malignant hematopoietic diseases may be related with thrombophilia; The expressions of CD62p, CDllb and PMA in each phase of malignant hematopoietic diseases are different; They could be used as helpful markers to observe therapeutic efficacy and evaluate turnover.